Corrigendum to: GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma

Sitansu S Nanda1, Md Imran Hossain1, Heongkyu Ju2

  • 1Department of Chemistry, Myongji University, Yongin, 03674, South Korea.

Current Drug Targets
|August 27, 2022
PubMed

Insights

This correction adds Georgia C. Papaefthymiou as a co-author to the article "GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma," published in Current Drug Targets. The update ensures accurate author attribution for the research.

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Pharmacology

Background:

  • The original article focused on Glycogen Synthase Kinase 3 (GSK-3) inhibitors.
  • Colon carcinoma is a significant area of cancer research.

Purpose of the Study:

  • To correct the author list of a previously published article.
  • To include Georgia C. Papaefthymiou as a co-author.

Main Methods:

  • Correction of author information in a published scientific article.
  • Ensuring accurate citation and attribution.

Main Results:

  • Georgia C. Papaefthymiou has been officially added as a co-author.
  • The corrected author list is now reflected in the article.

Conclusions:

  • Accurate author attribution is crucial for scientific integrity.
  • This correction ensures proper credit for all contributors to the research on GSK-3 inhibitors and colon carcinoma.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.8K
GTPases and their Regulation02:14

GTPases and their Regulation

2.3K